Exact Mass: 480.1851
Exact Mass Matches: 480.1851
Found 500 metabolites which its exact mass value is equals to given mass value 480.1851
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Acevaltrate
Production by Valeriana subspecies Acevaltrate is found in tea, fats and oils, and herbs and spices. Acevaltrate is found in fats and oils. Acevaltrate is produced by Valeriana specie C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic Acevaltrate inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively[1]. Acevaltrate inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively[1].
1-alpha-Acevaltrate
Constituent of Valeriana species 1-alpha-Acevaltrate is found in tea, fats and oils, and herbs and spices. 1-alpha-Acevaltrate is found in fats and oils. 1-alpha-Acevaltrate is a constituent of Valeriana sp.
5alpha-Pregnan-3beta,20alpha-diol disulfate
5alpha-Pregnan-3beta,20alpha-diol disulfate, also known as 5α-pregnan-3β,20α-ylene sulfate, belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton. 5alpha-Pregnan-3beta,20alpha-diol disulfate is an extremely strong acidic compound (based on its pKa). 5alpha-Pregnan-3beta,20alpha-diol disulfate can be found in feces. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
5alpha-Pregnan-3beta,20beta-diol disulfate
5alpha-Pregnan-3beta,20beta-diol disulfate belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton. 5alpha-Pregnan-3beta,20beta-diol disulfate has been identified in the human placenta (PMID: 32033212).
5alpha-Pregnan-3alpha,20beta-diol disulfate
5alpha-Pregnan-3alpha,20beta-diol disulfate belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton. 5alpha-Pregnan-3alpha,20beta-diol disulfate is possibly neutral. 5alpha-Pregnan-3alpha,20beta-diol disulfate has been identified in the human placenta (PMID: 32033212).
(2S)-2-Amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoylcarnitine
(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoylcarnitine is an acylcarnitine. More specifically, it is an (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
[10,13-Dimethyl-17-(1-sulfooxyethyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
beclomethasone propionate
trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran
(4S,7S,12Br)-7-[[(2R)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
Tucatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EH - Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
(aS)-(5R,7R)-5,6,7,8-tetrahydro-13,14-dimethoxy-7-methyl-6-methylene-1,3-benzodioxolo[5,6:3,4]cycloocta[1,2-f][1,3]benzodioxol-5-yl (2Z)-2-methylbut-enoate|schisandrene A
8beta-hydroxy-teucrolivin B|8??-Hydroxy-teucrolivin B
2-Hydroxy-5-[(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy]-4,6-dimethylbenzoic acid 3-hydroxy-2,4,5-trimethylphenyl ester
4-[[4-hydroxy-3-[2-(4-hydroxyphenyl)ethynyl][1,1-biphenyl]-2-yl](4-methoxyphenyl)methylene]-2,5-cyclohexadien-1-one|selaginellin N
3,3,4,5-tetramethoxybibenzyl-4-O-beta-D-glucopyranoside
1,7-bis-(3,4-dihydoxyphenyl)-5-hydroxy-heptane-3-O-beta-D-xylopyranoside
1(O)-acetyl-8alpha-acetoxy-10beta-hydroxy-hirsutinolide 1(O)-isovalerate
(1R*,4R*,5R*,6R*,8S*,10R*)-1,4-Dihydroxy-5,13-diacetoxy-8-tiglyloxycadin-7(11)-en-6,12-olide
Phe Asp Ala Glu
(E)-1-(glutathion-S-yl)-N-hydroxy-omega-(methylsulfanyl)heptan-1-imine
Acevaltrate
Acevaltrate is a fatty acid ester. Acevaltratum is a natural product found in Fedia cornucopiae, Plectritis macrocera, and other organisms with data available. C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic Acevaltrate inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively[1]. Acevaltrate inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively[1].
[3-(13-methyltetradecyl)-5-sulfooxyphenyl] hydrogen sulfate
Ala Asp Glu Phe
Ala Asp Phe Glu
Ala Glu Asp Phe
Ala Glu Phe Asp
Ala Glu Met Met
Ala Phe Asp Glu
Ala Phe Glu Asp
Ala Met Glu Met
Ala Met Met Glu
Ala Met Pro Tyr
Ala Met Tyr Pro
Ala Asn Asn Tyr
Ala Asn Tyr Asn
Ala Pro Met Tyr
Ala Pro Tyr Met
Ala Tyr Met Pro
Ala Tyr Asn Asn
Ala Tyr Pro Met
Cys Cys Lys Gln
Cys Cys Gln Lys
Cys Asp Phe Pro
Cys Asp Ile Met
Cys Asp Leu Met
Cys Asp Met Ile
Cys Asp Met Leu
Cys Asp Pro Phe
Cys Glu Met Val
Cys Glu Val Met
Cys Phe Asp Pro
Cys Phe Pro Asp
Cys Ile Asp Met
Cys Ile Met Asp
Cys Lys Cys Gln
Cys Lys Gln Cys
Cys Leu Asp Met
Cys Leu Met Asp
Cys Met Asp Ile
Cys Met Asp Leu
Cys Met Glu Val
Cys Met Ile Asp
Cys Met Leu Asp
Cys Met Val Glu
Cys Pro Asp Phe
Cys Pro Phe Asp
Cys Pro Val Tyr
Cys Pro Tyr Val
Cys Gln Cys Lys
Cys Gln Lys Cys
Cys Val Glu Met
Cys Val Met Glu
Cys Val Pro Tyr
Cys Val Tyr Pro
Cys Tyr Pro Val
Cys Tyr Val Pro
Asp Ala Glu Phe
Asp Ala Phe Glu
Asp Cys Phe Pro
Asp Cys Ile Met
Asp Cys Leu Met
Asp Cys Met Ile
Asp Cys Met Leu
Asp Cys Pro Phe
Asp Glu Ala Phe
Asp Glu Phe Ala
Asp Phe Ala Glu
Asp Phe Cys Pro
Asp Phe Glu Ala
Asp Phe Pro Cys
Asp Ile Cys Met
Asp Ile Met Cys
Asp Leu Cys Met
Asp Leu Met Cys
Asp Met Cys Ile
Asp Met Cys Leu
Asp Met Ile Cys
Asp Met Leu Cys
Asp Pro Cys Phe
Asp Pro Phe Cys
Asp Pro Ser Tyr
Asp Pro Tyr Ser
Asp Ser Pro Tyr
Asp Ser Tyr Pro
Asp Tyr Pro Ser
Asp Tyr Ser Pro
Glu Ala Asp Phe
Glu Ala Phe Asp
Glu Ala Met Met
Glu Cys Met Val
Glu Cys Val Met
Glu Asp Ala Phe
Glu Asp Phe Ala
Glu Glu Phe Gly
Glu Glu Gly Phe
Glu Phe Ala Asp
Glu Phe Asp Ala
Glu Phe Glu Gly
Glu Phe Gly Glu
Glu Gly Glu Phe
Glu Gly Phe Glu
Glu Met Ala Met
Glu Met Cys Val
Glu Met Met Ala
Glu Met Thr Thr
Glu Met Val Cys
Glu Thr Met Thr
Glu Thr Thr Met
Glu Val Cys Met
Glu Val Met Cys
Phe Ala Asp Glu
Phe Ala Glu Asp
Phe Cys Asp Pro
Phe Cys Pro Asp
Phe Asp Cys Pro
Phe Asp Glu Ala
Phe Asp Pro Cys
Phe Glu Ala Asp
Phe Glu Asp Ala
Phe Glu Glu Gly
Phe Glu Gly Glu
Phe Gly Glu Glu
Phe Met Pro Ser
Phe Met Ser Pro
Phe Asn Asn Ser
Phe Asn Ser Asn
Phe Pro Cys Asp
Phe Pro Asp Cys
Phe Pro Met Ser
Phe Pro Ser Met
Phe Ser Met Pro
Phe Ser Asn Asn
Phe Ser Pro Met
Gly Glu Glu Phe
Gly Glu Phe Glu
Gly Phe Glu Glu
Gly His His Met
Gly His Met His
Gly Met His His
Gly Asn Gln Tyr
Gly Asn Tyr Gln
Gly Gln Asn Tyr
Gly Gln Tyr Asn
Gly Tyr Asn Gln
Gly Tyr Gln Asn
His Gly His Met
His Gly Met His
His His Gly Met
His His Met Gly
His Met Gly His
His Met His Gly
Ile Cys Asp Met
Ile Cys Met Asp
Ile Asp Cys Met
Ile Asp Met Cys
Ile Met Cys Asp
Ile Met Asp Cys
Lys Cys Cys Gln
Lys Cys Gln Cys
Lys Gln Cys Cys
Leu Cys Asp Met
Leu Cys Met Asp
Leu Asp Cys Met
Leu Asp Met Cys
Leu Met Cys Asp
Leu Met Asp Cys
Met Ala Glu Met
Met Ala Met Glu
Met Ala Pro Tyr
Met Ala Tyr Pro
Met Cys Asp Ile
Met Cys Asp Leu
Met Cys Glu Val
Met Cys Ile Asp
Met Cys Leu Asp
Met Cys Val Glu
Met Asp Cys Ile
Met Asp Cys Leu
Met Asp Ile Cys
Met Asp Leu Cys
Met Glu Ala Met
Met Glu Cys Val
Met Glu Met Ala
Met Glu Thr Thr
Met Glu Val Cys
Met Phe Pro Ser
Met Phe Ser Pro
Met Gly His His
Met His Gly His
Met His His Gly
Met Ile Cys Asp
Met Ile Asp Cys
Met Leu Cys Asp
Met Leu Asp Cys
Met Met Ala Glu
Met Met Glu Ala
Met Pro Ala Tyr
Met Pro Phe Ser
Met Pro Ser Phe
Met Pro Tyr Ala
Met Ser Phe Pro
Met Ser Pro Phe
Met Thr Glu Thr
Met Thr Thr Glu
Met Val Cys Glu
Met Val Glu Cys
Met Tyr Ala Pro
Met Tyr Pro Ala
Asn Ala Asn Tyr
Asn Ala Tyr Asn
Asn Phe Asn Ser
Asn Phe Ser Asn
Asn Gly Gln Tyr
Asn Gly Tyr Gln
Asn Asn Ala Tyr
Asn Asn Phe Ser
Asn Asn Ser Phe
Asn Asn Tyr Ala
Asn Gln Gly Tyr
Asn Gln Tyr Gly
Asn Ser Phe Asn
Asn Ser Asn Phe
Asn Tyr Ala Asn
Asn Tyr Gly Gln
Asn Tyr Asn Ala
Asn Tyr Gln Gly
Pro Ala Met Tyr
Pro Ala Tyr Met
Pro Cys Asp Phe
Pro Cys Phe Asp
Pro Cys Val Tyr
Pro Cys Tyr Val
Pro Asp Cys Phe
Pro Asp Phe Cys
Pro Asp Ser Tyr
Pro Asp Tyr Ser
Pro Phe Cys Asp
Pro Phe Asp Cys
Pro Phe Met Ser
Pro Phe Ser Met
Pro Met Ala Tyr
Pro Met Phe Ser
Pro Met Ser Phe
Pro Met Tyr Ala
Pro Ser Asp Tyr
Pro Ser Phe Met
Pro Ser Met Phe
Pro Ser Tyr Asp
Pro Val Cys Tyr
Pro Val Tyr Cys
Pro Tyr Ala Met
Pro Tyr Cys Val
Pro Tyr Asp Ser
Pro Tyr Met Ala
Pro Tyr Ser Asp
Pro Tyr Val Cys
Gln Cys Cys Lys
Gln Cys Lys Cys
Gln Gly Asn Tyr
Gln Gly Tyr Asn
Gln Lys Cys Cys
Gln Asn Gly Tyr
Gln Asn Tyr Gly
Gln Tyr Gly Asn
Gln Tyr Asn Gly
Ser Asp Pro Tyr
Ser Asp Tyr Pro
Ser Phe Met Pro
Ser Phe Asn Asn
Ser Phe Pro Met
Ser Met Phe Pro
Ser Met Pro Phe
Ser Asn Phe Asn
Ser Asn Asn Phe
Ser Pro Asp Tyr
Ser Pro Phe Met
Ser Pro Met Phe
Ser Pro Tyr Asp
Ser Tyr Asp Pro
Ser Tyr Pro Asp
Thr Glu Met Thr
Thr Glu Thr Met
Thr Met Glu Thr
Thr Met Thr Glu
Thr Thr Glu Met
Thr Thr Met Glu
Val Cys Glu Met
Val Cys Met Glu
Val Cys Pro Tyr
Val Cys Tyr Pro
Val Glu Cys Met
Val Glu Met Cys
Val Met Cys Glu
Val Met Glu Cys
Val Pro Cys Tyr
Val Pro Tyr Cys
Val Tyr Cys Pro
Val Tyr Pro Cys
Tyr Ala Met Pro
Tyr Ala Asn Asn
Tyr Ala Pro Met
Tyr Cys Pro Val
Tyr Cys Val Pro
Tyr Asp Pro Ser
Tyr Asp Ser Pro
Tyr Gly Asn Gln
Tyr Gly Gln Asn
Tyr Met Ala Pro
Tyr Met Pro Ala
Tyr Asn Ala Asn
Tyr Asn Gly Gln
Tyr Asn Asn Ala
Tyr Asn Gln Gly
Tyr Pro Ala Met
Tyr Pro Cys Val
Tyr Pro Asp Ser
Tyr Pro Met Ala
Tyr Pro Ser Asp
Tyr Pro Val Cys
Tyr Gln Gly Asn
Tyr Gln Asn Gly
Tyr Ser Asp Pro
Tyr Ser Pro Asp
Tyr Val Cys Pro
Tyr Val Pro Cys
1-a-Acevaltrate
[1,1-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-5-yl ester
Sulfatinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
2-(4-Chloro-3-(3-(1-hydroxycycloheptyl)propanoyl)phenyl)-4-((2R)-2-hydroxy-3-methoxy-propyl)-1,2,4-triazine-3,5-dione
CE-224535 is a selective P2X7 receptor antagonist.
1,2,3-Propanetricarboxylic acid, 2-[(trimethylsilyl)oxy]-, tris(trimethylsilyl) ester
Tucatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EH - Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
[3-(4-{[3,3-Bis(hydroxymethyl)azetidin-1-yl]methyl}phenoxy)azetidin-1-yl][5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methanone
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(E)-N-hydroxy-C-(6-methylsulfanylhexyl)carbonimidoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
[9-Chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-1-yl] propanoate
(2S)-2-Amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoylcarnitine
7-[(2-acetylsulfanyl-3-phenylpropanoyl)amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
N,N,N-tris(3-pyridylmethyl)benzene-1,3,5-tricarboxamide
6-amino-1,3-diphenyl-4-(3,4,5-trimethoxyphenyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile
4-[4-Oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester
N,N,N-tris(4-pyridylmethyl)benzene-1,3,5-tricarboxamide
7-[4-[4-(2,5-dimethylphenyl)-1-piperazinyl]-4-oxobutyl]-6-sulfanylidene-5H-[1,3]dioxolo[4,5-g]quinazolin-8-one
2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methylanilino)-N-(2-furanylmethyl)-2-(3-pyridinyl)acetamide
(2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propyl-N-(1,3-thiazol-2-yl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propyl-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3,5-dimethyl-4-isoxazolesulfonamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3,5-dimethyl-4-isoxazolesulfonamide
N-[(1R,3R,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3,5-dimethyl-4-isoxazolesulfonamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3,5-dimethyl-4-isoxazolesulfonamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3,5-dimethyl-4-isoxazolesulfonamide
N-[(1S,3S,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aR,9aS)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(cyclopropylmethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
(20R)-5alpha-pregnane-3,20-diyl bis(hydrogen sulfate)
(2S,3R,4S)-3-ethenyl-4-[(E)-2-[1-(2-hydroxyethyl)pyridin-1-ium-3-yl]ethenyl]-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid
Pregnane-3,20-diol 3,20-disulfate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
(11r,13r)-3,22-dimethoxy-13-methyl-12-methylidene-5,7,18,20-tetraoxapentacyclo[13.7.0.0²,¹⁰.0⁴,⁸.0¹⁷,²¹]docosa-1(22),2(10),3,8,15,17(21)-hexaen-11-yl (2z)-2-methylbut-2-enoate
n-[(2s,3r,4r,6r)-3,16-dihydroxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),16,20(27),21(26),22,24-decaen-4-yl]ethanimidic acid
(1r,6r,7r,7as)-4-[(acetyloxy)methyl]-1-[(3-methylbutanoyl)oxy]-6,7a-dihydro-1h-spiro[cyclopenta[c]pyran-7,2'-oxiran]-6-yl 3-(acetyloxy)-3-methylbutanoate
(1r,2r,3s,4s,5r,8r,9r,10r,12z,14s,17r)-10-(acetyloxy)-4,5,9-trihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadeca-6,12-dien-2-yl acetate
methyl 8-hydroxy-10-(hydroxymethyl)-3-methylidene-4,5-bis[(2-methylpropanoyl)oxy]-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-6-carboxylate
(1r,2s,4as,5r,6r,8r,8ar)-2-(acetyloxy)-5-[2-(furan-3-yl)ethyl]-4a,6,8-trihydroxy-5,6-dimethyl-7-oxo-tetrahydrospiro[naphthalene-1,2'-oxiran]-8a-ylmethyl acetate
(4s,5r,6r)-18-hydroxy-5-methoxy-6-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-decaen-16-one
(1r,2s,6r,7r,9s,12s,13s)-12-(acetyloxy)-13-(hydroxymethyl)-9-methyl-5-methylidene-4-oxo-3,14-dioxatricyclo[7.4.1.0²,⁶]tetradecan-7-yl (2z)-2-[(acetyloxy)methyl]but-2-enoate
13-[(acetyloxy)methyl]-12-hydroxy-9-methyl-5-methylidene-4-oxo-3,14-dioxatricyclo[7.4.1.0²,⁶]tetradecan-7-yl 4-(acetyloxy)-2-methylbut-2-enoate
(1r,2s,3s,4r,6s,8s,11z)-3-(acetyloxy)-11-{2-[(1r)-1-(acetyloxy)-3,3-dimethylcyclohexyl]ethylidene}-10-oxo-5,7,9-trioxatricyclo[6.3.0.0²,⁶]undecan-4-yl acetate
(2s)-3-hydroxy-1-{4-methoxy-9h-pyrido[3,4-b]indol-1-yl}-2-({4-methoxy-9h-pyrido[3,4-b]indol-1-yl}methyl)propan-1-one
2-(acetyloxy)-5-[2-(furan-3-yl)ethyl]-4a,6,8-trihydroxy-5,6-dimethyl-7-oxo-tetrahydrospiro[naphthalene-1,2'-oxiran]-8a-ylmethyl acetate
8β-hydroxy-teucrolivin b
{"Ingredient_id": "HBIN013674","Ingredient_name": "8\u03b2-hydroxy-teucrolivin b","Alias": "NA","Ingredient_formula": "C24H32O10","Ingredient_Smile": "CC(=O)OCC12C(C(=O)C(C(C1(CCC(C23CO3)OC(=O)C)O)(C)CCC4=COC=C4)(C)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10760","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
acevaltrate
{"Ingredient_id": "HBIN014504","Ingredient_name": "acevaltrate","Alias": "NA","Ingredient_formula": "C24H32O10","Ingredient_Smile": "CC(C)CC(=O)OC1C2C(=CC(C23CO3)OC(=O)CC(C)(C)OC(=O)C)C(=CO1)COC(=O)C","Ingredient_weight": "480.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "534","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "137706187","DrugBank_id": "NA"}
ailantinol g
{"Ingredient_id": "HBIN014946","Ingredient_name": "ailantinol g","Alias": "NA","Ingredient_formula": "C24H32O10","Ingredient_Smile": "CCC(C)(C(=O)OC1C2C(C(C3(C4C2(CO3)C(CC4(C)C5C(=CC(=O)O5)C)OC1=O)O)O)C)O","Ingredient_weight": "480.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "780","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10896127","DrugBank_id": "NA"}